MLKL/retromer axis controls PD-L1 recycling to compromise antitumor immunity during VCP inhibition–induced necroptosis
Proceedings of the National Academy of Sciences · 23.12.2025 · 122 (51)
DOI: 10.1073/pnas.2518675122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 16.12.2025. Verfasst von Yang Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Ministry of Education Key Laboratory of Tumor Molecular Biology and State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdon…. Hauptthemen laut MEDLINE: Necroptosis, Valosin Containing Protein, B7-H1 Antigen, Protein Kinases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Key Research and Development Program of China (NKPs), MOST | National Natural Science Foundation of China (NSFC).
Abstract (Originalsprache)
The activation of the vesicular trafficking system, including endosomal recycling and extracellular vesicle (EV) release, represents an adaptive mechanism in cancer cells to counteract cellular stress or necroptotic death signals, which hampers cancer therapy. However, the underlying mechanisms remain poorly understood. Indeed, our study demonstrate that inhibition of valosin-containing protein (VCPi) induces EV release and necroptosis in colorectal cancer (CRC), but does not achieve a synergistic effect with immunotherapy. Mechanistically, VCPi delays the degradation of mixed lineage kinase domain-like protein (MLKL), a critical regulator of necroptosis and endosomal trafficking. Knockdown of MLKL reduces VCPi-mediated necroptosis, EV release, and programmed death ligand 1 (PD-L1) recycling. VCPi leads to MLKL accumulation, which recruits the retromer complex and GTPase-activating protein TBC1D5 to inactivate Rab7A. This redirects PD-L1-loaded vesicles to the cell surface via the retromer complex, thereby resulting in immunosuppression. Notably, targeting the retromer complex enhances the therapeutic efficacy of combined VCP inhibitors and anti-PD-L1 therapy in CRC, offering a promising immunotherapeutic strategy. Our study elucidates the role of the retromer complex in mediating PD-L1 recycling during VCPi-induced necroptosis and reveals that dual inhibition of VCP and the retromer complex potentiates immunotherapy efficacy in CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ministry of Education Key Laboratory of Tumor Molecular Biology and State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules…
- Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
ORCID-Profile: Yang Wang, Qing-Yu He
Förderung
- MOST | National Key Research and Development Program of China (NKPs)
- MOST | National Natural Science Foundation of China (NSFC)
Zitieren
APA
Wang, Y., Huang, Z. J., Yu, N. N., Liang, J. Z., Zeng, Y. H., Zhao, Q., Zhou, Y. P., Zeng, Y. J., Sun, Z. H., Zhang, S., He, Q. Y., & Zhang, J. (2025). MLKL/retromer axis controls PD-L1 recycling to compromise antitumor immunity during VCP inhibition–induced necroptosis. Proceedings of the National Academy of Sciences, 122(51). https://doi.org/10.1073/pnas.2518675122
Vancouver
Wang Y, Huang ZJ, Yu NN, Liang JZ, Zeng YH, Zhao Q, et al. MLKL/retromer axis controls PD-L1 recycling to compromise antitumor immunity during VCP inhibition–induced necroptosis. Proceedings of the National Academy of Sciences. 2025;122(51). doi:10.1073/pnas.2518675122
BibTeX
@article{Wang2025,
author = {Wang, Yang and Huang, Zi-Jia and Yu, Nan-Nan and Liang, Jun-Ze and Zeng, Yong-Hui and Zhao, Qian and Zhou, Yi-Ping and Zeng, Yu-Jie and Sun, Zheng-Hua and Zhang, Shuixing and He, Qing-Yu and Zhang, Jing},
title = {MLKL/retromer axis controls PD-L1 recycling to compromise antitumor immunity during VCP inhibition–induced necroptosis},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
volume = {122},
number = {51},
doi = {10.1073/pnas.2518675122}
}
EUVIMED